The VALORE project multi-database network has access to data on more than 140,000 biological drug users with immune-mediated inflammatory diseases (with a cumulative exposure of 507,745 person-years during the entire follow-up) from 13 Italian regions.

Overall, the cumulated amount of person-time of exposure to biological drugs approved for immune-mediated inflammatory diseases provides enough statistical power to investigate weak, moderate, and strong associations of almost all individual biological drugs and the most clinically relevant safety outcomes.

This distributed database network captured data on a large number of etanercept, adalimumab, and infliximab users who switched between originator and biosimilar during the entire follow-up, thus offering the opportunity to investigate interchangeability in a real-world setting.